Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy

Angewandte Chemie
doi 10.1002/ange.201809461
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Screen-Identified Selective Inhibitor of Lysine Demethylase 5A Blocks Cancer Cell Growth and Drug Resistance

Oncotarget
Oncology
2016English

Platinum-Based Therapy for Triple-Negative Breast Cancer Treatment: A Meta-Analysis

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Exploring Specific Prognostic Biomarkers in Triple-Negative Breast Cancer

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2019English

Triple-Negative Breast Cancer

2018English

A Review of Triple-Negative Breast Cancer

Cancer Control
MedicineOncologyHematology
2010English

Mp29-09 Novel Selective Lysine Specific Demethylase 1 Inhibitors Effectively Impair Castration Resistant Prostate Cancer Growth

Journal of Urology
Urology
2018English

Mp83-03 Novel Selective Lysine Specific Demethylase 1 Inhibitors Effectively Impair Castration Resistant Prostate Cancer Growth

Journal of Urology
Urology
2017English

Lysine-Specific Demethylase 2B (KDM2B; JHDM1B)

Science-Business eXchange
2014English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy